Literature DB >> 12630912

The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret.

Laura Cerchia1, Domenico Libri, Maria Stella Carlomagno, Vittorio de Franciscis.   

Abstract

Substitution of Cys-634 in the extracellular domain of the Ret tyrosine kinase receptor causes its dimerization and activation of its transforming potential. To gain further insight into the molecular basis leading to Ret activation we purified a mutant protein consisting of the entire ectodomain of the Ret carrying a Cys-634-->Tyr substitution (EC-Ret(C634Y)). The protein is glycosylated, like the native one, and is biologically active. By using an in vitro cell system we show that EC-Ret(C634Y) inhibits the membrane-bound receptor Ret(C634Y), interfering with its dimerization. Furthermore, we demonstrate that EC-Ret(C634Y) competes with the wild-type Ret receptor for ligand binding. The results presented support the notion of the possible involvment of glial cell line-derived neurotrophic factor (GDNF) with multiple endocrine neoplasia type 2A (MEN2A) tumours, and describe a useful tool for generating molecular mimetics directed towards specific mutations of the ret oncogene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12630912      PMCID: PMC1223439          DOI: 10.1042/BJ20021530

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  A generic protein purification method for protein complex characterization and proteome exploration.

Authors:  G Rigaut; A Shevchenko; B Rutz; M Wilm; M Mann; B Séraphin
Journal:  Nat Biotechnol       Date:  1999-10       Impact factor: 54.908

2.  The RET receptor: function in development and dysfunction in congenital malformation.

Authors:  S Manié; M Santoro; A Fusco; M Billaud
Journal:  Trends Genet       Date:  2001-10       Impact factor: 11.639

Review 3.  GDNF - a stranger in the TGF-beta superfamily?

Authors:  M Saarma
Journal:  Eur J Biochem       Date:  2000-12

Review 4.  The GDNF/RET signaling pathway and human diseases.

Authors:  M Takahashi
Journal:  Cytokine Growth Factor Rev       Date:  2001-12       Impact factor: 7.638

5.  GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.

Authors:  S Jing; D Wen; Y Yu; P L Holst; Y Luo; M Fang; R Tamir; L Antonio; Z Hu; R Cupples; J C Louis; S Hu; B W Altrock; G M Fox
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

6.  A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.

Authors:  D Califano; A D'Alessio; G L Colucci-D'Amato; G De Vita; C Monaco; G Santelli; P P Di Fiore; G Vecchio; A Fusco; M Santoro; V de Franciscis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

7.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.

Authors:  M Santoro; F Carlomagno; A Romano; D P Bottaro; N A Dathan; M Grieco; A Fusco; G Vecchio; B Matoskova; M H Kraus
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

8.  The ret-Activating Ligand GDNF Is Differentiative and Not Mitogenic for Normal and Neoplastic Human Chromaffin Cells In Vitro.

Authors:  James F. Powers; Panayiotis Tsokas; Arthur S. Tischler
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

9.  Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.

Authors:  G Romeo; P Ronchetto; Y Luo; V Barone; M Seri; I Ceccherini; B Pasini; R Bocciardi; M Lerone; H Kääriäinen
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

10.  Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK.

Authors:  G L Colucci-D'Amato; A D'Alessio; D Califano; G Cali; C Rizzo; L Nitsch; G Santelli; V de Franciscis
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

View more
  4 in total

Review 1.  RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

2.  Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase.

Authors:  Laura Cerchia; Frédéric Ducongé; Carine Pestourie; Jocelyne Boulay; Youssef Aissouni; Karine Gombert; Bertrand Tavitian; Vittorio de Franciscis; Domenico Libri
Journal:  PLoS Biol       Date:  2005-03-22       Impact factor: 8.029

3.  Differential SELEX in human glioma cell lines.

Authors:  Laura Cerchia; Carla Lucia Esposito; Andreas H Jacobs; Bertrand Tavitian; Vittorio de Franciscis
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

4.  A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation.

Authors:  Carla Lucia Esposito; Amelia D'Alessio; Vittorio de Franciscis; Laura Cerchia
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.